<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cloxacillin (United States: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cloxacillin (United States: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Cloxacillin (United States: Not available): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="12335" href="/d/html/12335.html" rel="external">see "Cloxacillin (United States: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52866409"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>JAMP-Cloxacillin;</li>
<li>TEVA-Cloxacillin</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F153901"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic, Penicillin</li></ul></div>
<div class="block doa drugH1Div" id="F153887"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dose and duration of therapy can vary depending on infecting organism, severity of infection, and clinical response of patient. Treat severe staphylococcal infections for at least 14 days; endocarditis and osteomyelitis require an extended duration of therapy for 4 to 6 weeks. The intravenous route should be used for severe infections.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Usual dosage range:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 250 to 500 mg every 6 hours; may increase dose for serious infections (maximum dose: 6 g/day).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM, IV:</b> 1 to 2 g every 4 to 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25614044','lexi-content-ref-15138315','lexi-content-ref-26320109','lexi-content-ref-19307354','lexi-content-ref-WHO.2001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25614044','lexi-content-ref-15138315','lexi-content-ref-26320109','lexi-content-ref-19307354','lexi-content-ref-WHO.2001'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="40115e5d-8c48-44bc-9d19-50165583a2c9">Bloodstream infection due to methicillin-susceptible <i>S. aureus</i></span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bloodstream infection due to methicillin-susceptible <i>S. aureus</i>: IV:</b> 2 g every 4 to 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25614044','lexi-content-ref-30173161','lexi-content-ref-WHO.2001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25614044','lexi-content-ref-30173161','lexi-content-ref-WHO.2001'])">Ref</a></span>); treat uncomplicated <i>S. aureus</i> bacteremia for ≥14 days starting from day of first negative blood culture, with longer courses warranted for endocarditis or metastatic sites of infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19489710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19489710'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e766db72-b222-41be-a4f0-da41f6c04f7d">Endocarditis due to methicillin-susceptible staphylococci</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis due to methicillin-susceptible staphylococci:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Native valve:</i>
<b>IV:</b> 12 g/day in 4 to 6 divided doses for 4 to 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26320109']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26320109'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prosthetic valve:</i>
<b>IV:</b> 12 g/day in 4 to 6 divided doses for ≥6 weeks, in combination with rifampin and gentamicin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26320109']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26320109'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d5d68ebc-4429-44f4-be54-b879810ceaf3">Osteomyelitis due to methicillin-susceptible <i>S. aureus</i></span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteomyelitis due to methicillin-susceptible <i>S. aureus</i>:</b>
<b>IV:</b> 2 g every 4 hours for ≥6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19307354']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19307354'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5fe294fd-4626-4e48-9579-84675accedc8">Skin and soft tissue infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Localized purulent skin lesions, impetigo: <b>Oral:</b> 250 to 500 mg every 6 hours for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-WHO.2001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-WHO.2001'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990272"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Kidney impairment prior to treatment initiation:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:8em;">CrCl ≥10 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl &lt;10 mL/minute: No specific dosage adjustment recommended; however, monitor patients closely as studies conducted in critically ill patients with severe kidney impairment have found supratherapeutic cloxacillin concentrations (eg, &gt;100 mg/L) in this population as well as neurotoxicity and nephrotoxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34204743','lexi-content-ref-25582344','lexi-content-ref-35984543','lexi-content-ref-28332157','lexi-content-ref-22005059']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34204743','lexi-content-ref-25582344','lexi-content-ref-35984543','lexi-content-ref-28332157','lexi-content-ref-22005059'])">Ref</a></span>). When treating less severe infections, consider limiting dose to 8 g/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Export.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Export.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not significantly dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4595633']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4595633'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral, IV:</b> Dose as per CrCl &lt;10 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Export.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Export.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzed (highly protein bound) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Export.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Export.DOR'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral, IV:</b> Dose as per CrCl &lt;10 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Export.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Export.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CRRT:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) and minimal residual kidney function unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection). Close monitoring of response and adverse reactions (eg, neurotoxicity) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral, IV:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Export.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Export.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection). Close monitoring of response and adverse reactions (eg, neurotoxicity) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral, IV:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Export.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Export.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Nephrotoxicity during treatment</i>:</b> Nephrotoxicity has been reported with cloxacillin use, particularly in patients receiving high-dose IV therapy (eg, ≥8 g per day). Risk factors include older age (eg, &gt;75 years of age) and concomitant use of other nephrotoxins. If acute kidney injury occurs, discontinue cloxacillin and administer an alternate antibiotic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34204743','lexi-content-ref-29665445','lexi-content-ref-36401785','lexi-content-ref-35740176']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34204743','lexi-content-ref-29665445','lexi-content-ref-36401785','lexi-content-ref-35740176'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987477"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doe drugH1Div" id="F153888"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F153895"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dose and duration of therapy can vary depending on infecting organism, severity of infection, and clinical response of patient. Treat severe staphylococcal infections for at least 14 days; endocarditis and osteomyelitis require an extended duration of therapy for 4 to 6 weeks. The intravenous route should be used for severe infections.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dac4e57c-0935-4a97-9247-ad53a6faa20a">Susceptible infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Susceptible infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>): </b></p>
<p style="text-indent:-2em;margin-left:4em;">Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≤20 kg: 25 to 50 mg/kg/day in divided doses every 6 hours</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents &gt;20 kg: Refer to adult dosing.</p>
<p style="text-indent:-2em;margin-left:4em;">IM, IV:</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≤20 kg: 25 to 50 mg/kg/day in divided doses every 6 hours. <b>Note:</b> Doses up to 50 mg/kg/dose every 4 to 6 hours or 200 mg/kg to 300 mg/kg/day in divided doses have been recommended by others (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17259425','lexi-content-ref-7284928']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17259425','lexi-content-ref-7284928'])">Ref</a></span>) (also see indication-specific dosing).</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents &gt;20 kg: Refer to adult dosing.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b3f666a0-865d-41db-be03-bac5522781ae">Arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Arthritis (septic) (off-label dosing) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-WHO.2001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-WHO.2001'])">Ref</a></span>):</b> Empiric therapy: Infants ≥2 months, Children, and Adolescents: IM, IV: 25 to 50 mg/kg/dose (maximum: 2 g/dose) every 6 hours with concomitant ceftriaxone</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="85e77c25-b70c-469f-9f0d-c2e23d6b29ed">Methicillin-sensitive <i>Staphylococcus aureus</i></span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Methicillin-sensitive <i>Staphylococcus aureus</i> (MSSA) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-WHO.2001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-WHO.2001'])">Ref</a></span>): </b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥2 months and Children ≤5 years: IM, IV: 25 to 50 mg/kg/dose (maximum: 2 g/dose) every 4 to 6 hours with concomitant ceftriaxone for 4 to 6 days or until clinical improvement, <b>followed by</b> oral cloxacillin 12.5 mg/kg/dose (maximum: 500 mg/dose) every 6 hours; total duration of therapy 2 to 3 weeks</p>
<p style="text-indent:-2em;margin-left:4em;">Children &gt;5 years and Adolescents: IM, IV: 25 to 50 mg/kg/dose (maximum: 2 g/dose) every 4 to 6 hours (maximum daily dose: 12 g/day) for 4 to 6 days or until clinical improvement, <b>followed by</b> oral cloxacillin 25 mg/kg/dose (maximum: 500 mg/dose) every 6 hours; total duration of therapy 2 to 3 weeks</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="da36b131-13ff-4e28-b905-1acb141aff64">Endocarditis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis (MSSA) (off-label dosing) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-WHO.2001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-WHO.2001'])">Ref</a></span>):</b> Children and Adolescents: IV: 50 mg/kg/dose (maximum: 2 g/dose) every 4 hours for 6 weeks; with concomitant gentamicin for initial 7 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a9d9ff41-d96a-4eb8-b9f5-e76594705fc3">Osteomyelitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteomyelitis (off-label dosing) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-WHO.2001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-WHO.2001'])">Ref</a></span>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Haemophilus influenza</i> or unknown pathogen: Infants ≥2 months and Children ≤5 years: IM, IV: 25 to 50 mg/kg/dose (maximum: 2 g/dose) every 4 to 6 hours with concomitant ceftriaxone for 4 to 6 days or until clinical improvement, <b>followed by</b> oral therapy with amoxicillin/clavulanate; total duration of therapy 3 to 4 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">MSSA:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥2 months and Children ≤5 years: IM, IV: 25 to 50 mg/kg/dose (maximum: 2 g/dose) every 4 to 6 hours with concomitant ceftriaxone for 4 to 6 days until clinical improvement, <b>followed by</b> oral cloxacillin 12.5 mg/kg/dose (maximum: 500 mg/dose) every 6 hours; total duration of therapy 3 to 4 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">Children &gt;5 years and Adolescents: IM, IV: 25 to 50 mg/kg/dose (maximum: 2 g/dose) every 4 to 6 hours (maximum daily dose: 12 g/day) for 4 to 6 days until clinical improvement, <b>followed by</b> oral cloxacillin 25 mg/kg/dose (maximum: 500 mg/dose) every 6 hours; total duration of therapy 3 to 4 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Salmonella spp:</i> Infants ≥2 months and Children ≤5 years: IM, IV: 25 to 50 mg/kg/dose (maximum: 2 g/dose) every 4 to 6 hours with concomitant ceftriaxone for 4 to 6 days or until clinical improvement, <b>followed by</b> oral therapy with sulfamethoxazole/trimethoprim or amoxicillin or ciprofloxacin; total duration of therapy 6 weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5467e416-8f22-403d-abb5-8c48847846b4">Pneumonia, MSSA</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, MSSA (off-label dosing) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-WHO.2001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-WHO.2001'])">Ref</a></span>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥2 months and Children ≤5 years: Oral: 25 to 50 mg/kg/dose (maximum: 2 g/dose) every 6 hours for at least 3 weeks with concomitant gentamicin.</p>
<p style="text-indent:-2em;margin-left:4em;">Children &gt;5 years and Adolescents: IM, IV: 50 mg/kg/dose (maximum: 2 g/dose) every 6 hours for 10 to 14 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ba4d4412-a155-49ca-8ebd-47486ba5bb56">Pneumonia, nosocomial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, nosocomial (off-label dosing) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-WHO.2001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-WHO.2001'])">Ref</a></span>):</b> Empiric therapy: Children and Adolescents: IV: 50 mg/kg/dose (maximum: 2 g/dose) every 6 hours with concomitant gentamicin for 7 days (add vancomycin for 10 to 14 days if in a hospital with a high prevalence of MRSA).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6ff7de4a-8a1e-4998-9772-3cf50eb92f0c">Septicemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Septicemia (off-label dosing) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-WHO.2001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-WHO.2001'])">Ref</a></span>):</b> Empiric therapy:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥2 months to 5 years: IV: 50 mg/kg/dose (maximum: 2 g/dose) every 4 to 6 hours with concomitant ceftriaxone.</p>
<p style="text-indent:-2em;margin-left:4em;">Children &gt;5 years and Adolescents: IV: 2 g every 4 to 6 hours with concomitant gentamicin.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5fe294fd-4626-4e48-9579-84675accedc8">Skin and soft tissue infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection (off-label dosing) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-WHO.2001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-WHO.2001'])">Ref</a></span>)</b>: Empiric therapy:</p>
<p style="text-indent:-2em;margin-left:4em;">Contaminated soft tissue injuries: Children and Adolescents: IM, IV: 25 to 50 mg/kg/dose (maximum: 2 g/dose) every 6 hours for 5 to 10 days with concomitant gentamicin and metronidazole; with clinical improvement, may switch to oral cloxacillin 12.5 to 25 mg/kg/dose (maximum: 500 mg) every 6 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Localized purulent skin lesions, impetigo: Children and Adolescents: Oral: 12.5 to 25 mg/kg/dose (maximum: 500 mg/dose) every 6 hours for 5 to 7 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Pyomyositis: Children and Adolescents: IM, IV: 25 to 50 mg/kg/dose (maximum: 2 g/dose) every 6 hours for 5 to 10 days; with clinical improvement, may switch to oral cloxacillin 12.5 to 25 mg/kg/dose (maximum: 500 mg/dose) every 6 hours.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51090176"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block dohp drugH1Div" id="F51090177"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F153855"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified. Reactions listed are based on reports for other agents in this same pharmacologic class and may not be specifically reported for cloxacillin.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Thrombophlebitis (IV)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis (Choon 2018), erythematous maculopapular rash (Moreno-Ancillo 2003)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypokalemia (Nagasayi 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: <i>Clostridioides difficile</i> colitis, diarrhea, epigastric discomfort, esophagitis (Zezos 2016), flatulence, hairy tongue, loose stools, nausea, stomatitis, vomiting (St John 1981)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria (St John 1981)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (Mani 2017), anemia, eosinophilia (Jayaweera 2018), granulocytopenia, hemolytic anemia, immune thrombocytopenia, leukopenia (St John 1981), neutropenia (Jayaweera 2018), thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic hepatitis (Goland 1998), cholestatic jaundice (Enat 1980), hepatic disease (vanishing bile duct syndrome) (Faragalia 2022), hepatotoxicity, increased serum alkaline phosphatase, increased serum transaminases (including increased serum alanine aminotransferase and increased serum aspartate aminotransferase) (St. John 1981)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema, hypersensitivity angiitis (Garcia-Porrua 1999), hypersensitivity reaction (Rodriguez-Jimenez 2009), type IV hypersensitivity reaction (Moreno-Ancillo 2003)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Interstitial nephritis (Grimm 1989) renal tubular disease</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F153870"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to cloxacillin, other penicillins, cephalosporins, or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F153852"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylactoid/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactoid) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity, history of sensitivity to multiple allergens, or previous IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria). Use with caution in asthmatic patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS effects: Although not reported with cloxacillin, the transport of penicillins across the blood-brain barrier may be enhanced by inflamed meninges or during cardiopulmonary bypass. An increased risk of myoclonia, seizures, or reduced consciousness may be observed in these patients (particularly those with renal failure).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic effects: Penicillin use has been associated with hematologic disorders (eg, agranulocytosis, neutropenia, thrombocytopenia) believed to be a hypersensitivity phenomena. Reactions are most often reversible upon discontinuing therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; rate of elimination is reduced.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorders: Use with caution in patients with a history of seizure disorder; high serum levels, particularly in the presence of renal impairment, may increase risk for seizures.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Neonates: May have decreased renal clearance of cloxacillin; frequent evaluation of serum levels and of clinical status for adverse effects as well as frequent dosage adjustments may be necessary in this patient population.</p></div>
<div class="block prod-avail drugH1Div" id="F11218424"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Not available in the US</p></div>
<div class="block geq drugH1Div" id="F53040719"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block dinfoc drugH1Div" id="F52866410"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg, 500 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg (1 ea); 1 g (1 ea); 2 g (1 ea); 10 g (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 125 mg/5 mL (60 mL, 100 mL, 200 mL)</p></div>
<div class="block adm drugH1Div" id="F6051127"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer with water 1 hour before or 2 hours after meals.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">IV push: Administer slowly over 2 to 4 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">IV infusion: Administer over 30 to 40 minutes.</p></div>
<div class="block admp drugH1Div" id="F52612445"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Administer into large muscle mass.</p>
<p style="text-indent:-2em;margin-left:4em;">IV push: Administer slowly over 2 to 4 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">IV infusion: Administer over 30 to 40 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer 1 to 2 hours before meals.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral solution: Shake well. Administer liquid with an accurate measuring device; do not use a household teaspoon (under- or overdosage may occur).</p></div>
<div class="block use drugH1Div" id="F153867"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Not approved in the United States.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Bacterial infections:</b> Treatment of bacterial infections (eg, bloodstream infection, endocarditis, pneumonia, bone and joint infections, skin and soft-tissue infections) caused by susceptible strains of penicillinase-producing staphylococci.</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Exhibits good activity against <i> Staphylococcus aureus</i>; has activity against many streptococci, but is less active than penicillin. Not effective against methicillin-resistant staphylococci.</p></div>
<div class="block cyt drugH1Div" id="F13299070"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OAT1/3</p></div>
<div class="block dri drugH1Div" id="F153857"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acemetacin: May increase the serum concentration of Penicillins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Penicillins may decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dichlorphenamide: Penicillins may enhance the hypokalemic effect of Dichlorphenamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Penicillins may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Penicillins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Benzoate: Penicillins may diminish the therapeutic effect of Sodium Benzoate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: May diminish the therapeutic effect of Penicillins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vancomycin: Cloxacillin may enhance the nephrotoxic effect of Vancomycin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Cloxacillin may diminish the anticoagulant effect of Vitamin K Antagonists. Cloxacillin may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F6050842"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food decreases cloxacillin absorption; serum levels are reduced by ~50%. Management: Administer with water on an empty stomach 1 hour before or 2 hours after meals.</p></div>
<div class="block pri drugH1Div" id="F6050840"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Penicillin class antibiotics cross the placenta in varying degrees. Cloxacillin is highly protein bound which may influence fetal exposure (Nau 1987).</p>
<p style="text-indent:0em;margin-top:2em;">As a class, penicillin antibiotics are widely used in pregnant women. Based on available data, penicillin antibiotics are generally considered compatible for use during pregnancy (Ailes 2016; Bookstaver 2015; Crider 2009; Damkier 2019; Lamont 2014; Muanda 2017a; Muanda 2017b).</p></div>
<div class="block brc drugH1Div" id="F20613757"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Cloxacillin is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Concentrations of penicillin class antibiotics in breast milk are limited (Nau 1987). Following a single dose of cloxacillin 500 mg IM to 2 or 3 women 5 to 7 days postpartum, breast milk concentrations were ≤0.4 mcg/mL over a 6-hour period, with the highest concentrations observed 4 to 6 hours after the maternal dose. In contrast, the highest maternal serum concentration (3.7 mcg/mL) was found 1 hour after the dose, decreasing to ≤0.3 mcg/mL 6 hours after the dose (Matsuda 1984).</p>
<p style="text-indent:-2em;margin-left:2em;">A prospective cohort study evaluated the outcomes of breastfed infants whose mothers were taking various medications. Among 10 mother-infant pairs with reported cloxacillin exposure (dose, duration, relationship to breastfeeding not provided), diarrhea was reported in 2 infants (Ito 1993).</p>
<p style="text-indent:-2em;margin-left:2em;">In general, antibiotics that are present in breast milk may cause non-dose-related modification of bowel flora. Monitor infants for GI disturbances, such as thrush or diarrhea. Cloxacillin is considered compatible with breastfeeding when used in usual recommended doses (WHO 2002).</p></div>
<div class="block mop drugH1Div" id="F153863"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Observe for signs and symptoms of anaphylaxis during first dose; CBC with differential (prior to initiating therapy and weekly thereafter), periodic urinalysis,  BUN, creatinine, hepatic function</p></div>
<div class="block pha drugH1Div" id="F153851"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibit the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>
<div class="block phk drugH1Div" id="F153869"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Oral: ~50%; reduced by food </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: Widely to most body fluids and bone; penetration into cells, into eye, and across normal meninges is poor; inflammation increases amount that crosses blood-brain barrier </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: ~94% (primarily albumin)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic to active and inactive metabolites </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 0.5 to 1.5 hours; prolonged with renal impairment and in neonates </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: Oral: ~1 hour </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine and feces</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F153874"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Monoclox | Orbenin</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">A-Clox | Adclox | Aldaclox | Ambeeclox | Aristoclox | Bactaclox | Betaclox | Biclox | Bitacep | Bpclox | Clobex | Cloxa | Cloxapen | Cloxi-Z | Cloxicap | Cloxiject | Cloxil | Cloxilin | Cloxima | Cloxin | Cloxisyrup | Cloxpen | Eclox | Ficlox | G-cloxacillin | Hi-Clox | Jp clox | Loxacin | Lysiclox | Miclocin | Navaclox | Neuclox | Omniclox | Penclox | Reclox | Remaclox | Simpiclox | Sinaclox | T-Clox | Tyclox | Ultraclox | Xeclox</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Orbenin | Penstaphon</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Cloxacilline</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Cloxacillin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Bactopen</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Orbenin</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Caxol</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Cloxacilina</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ao ge lin | Cloxacillin | Gao fen | Kai li | Kang ni li xing | Li da xin | Nuo kai | Pu kang bei | Rui pu lin | Tang nuo | Ya jun lin | Zhan ning</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Prostafilina a</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Orbenil</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Anaclosil | Cloxacilina Ips | Cloxacilina normon | Orbenin</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Clox | Cloxacillin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Ekvacillin | Staflocil</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Cloxacillin sandoz | Cloxacilline arrow | Cloxacilline biogaran | Cloxacilline eg | Cloxacilline mylan | Cloxacilline panpharma | Cloxacilline stragen | Cloxacilline zentiva | Cloxypen | Orbenine | Staphybiotic</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Cloxacillin | Cloxacillin cox | Orbenin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Anaclosil | Cloxacillin/Remedica | Orbenin | Staphyclox</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo-cloxi | Cloxa | Cloxacap | Cloxacillin | Cloxacin | Lidoxin | Monoclox | Orbenin | Syncillin</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Orbenin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Ikaclox | Meixam | Orbenin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Orbenin</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Loxavit | Orbenil</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Bioclox | Clin | Clopen | Cloxacillin | Cloxin | Klox | Nexiclox ds | Staphnil</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Monoclox | Prostaphlin A</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Methocillin s | Orbenin</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Cloxacillin | Cloxispa | Dawaclox | Kloxy | Mediclox | Nelox</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Orbrex</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Monoclox | Orbenin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Cloxacil | Cloxacillin | Cloxacilline | Cloxacilline arrow | Orbenin | Prostaphlin A</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Cloxacillin | Syntarpen</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Orbenin</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Cloxacillin</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Axocillin | Cloxa | Cloxabiotic | Cloxacap | Cloxacilla | Cloxacillin | Cloxacillin Pharmaniaga | Cloxcin | Cloxicap | Cloxil | Cloxillin | Dyna Cloxacillin | Isoxacillin | Loxamycin | Monoclox</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Cloxacillin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Cloxacilline gf | Orbenin</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Cloxacillin | Cloxacillin navamedic | Cloxacillin navamedic nordic | Cloxacillin stragen | Cloxacillin villerton | Ekvacillin</span>;</li>
<li>
<span class="countryCode">(OM)</span> <span class="country">Oman</span><span class="countrySeparator">: </span><span class="drugName">Cloxadar</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Cloxacilina | Prostafilina a</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Avastoph | Axillin | Boie cloxacillin | Caxin | Ciclox | Cillox | Clocsamed | Clofinil | Clonacil | Clopen | Clovex | Clox | Cloxacillin | Cloxacillin Diamond | Cloxacillin Interpharm | Cloxacillin Sydenham | Cloxacin | Cloxakid | Cloxal | Cloxalin | Cloxceena | Cloxid | Cloxigen | Cloxil | Cloxin | Cloxipen | Corstaph | Cyclox | Diacil | Diaclox | Dialox | Eloxil | Encloxil | Eraclox | Farmclox | Flactamacin | Kloxitas | Lewinex | Medaclox | Mediclox | Medix | Myreclox | Nacloxin | Nalixol | Nocloxol | Orbenin | Oxaclen | Oxeed | Pannox | Patriflex | Pharex cloxacillin | Prostaphlin A | RiteMED Cloxacillin | Secloxin | Solaze | Sydenclox | Vamcloxil | Vivarin | Zeflodan</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Auropen | Boschoclox | Cloxcin | Loxacin | Novoclox | Orbenin | Tabroclox</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Syntarpen</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Monoclox</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Monoclox | Orbenin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Cloxacillin stragen | Ekvacillin</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Apo-cloxi | Axocillin | Cloxacap | Cloxacillin | Cloxacillin stragen | Cloxcin | Cloxillin | Lidoxin | Monoclox | Orbenin | Procap-C</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Anaclosil | Cloxacilina normon | Cloxacillin stragen | Orbenin</span>;</li>
<li>
<span class="countryCode">(SL)</span> <span class="country">Sierra Leone</span><span class="countrySeparator">: </span><span class="drugName">Cloxacillin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Axocillin | C Cloxa | Cloxa | Cloxa m h | Cloxa T M N | Cloxacan | Cloxacap | Cloxacel | Cloxacillin | Cloxalin | Cloxam | Cloxamed | Cloxan | Cloxanbin | Cloxano | Cloxapan | Cloxasian | Cloxasin | Cloxasol | Cloxatin | Cloxcillin | Cloxcin | Cloxgen | Cloxil | Cloxin | Cloxino | Cloxlin | Cloxolen | Cloxomed | Cloxpac | Cloxstar | Coclox | Corbin | Greater-gloxa | K-cil | Kressxalin | Lidoxin | Lincox | Loxzalin | Medcloxa | Meiclox | Monoclox | Orbenin | Panoxilin | Pharclox | Pinclox | S Cloxin | Serviclox | Sinocloxin | Socloxin | Specclox | Staphoclox | Syntoclox | Theraclox | Ticlox | Vaclox | Vicloxa | Xalin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Cloxacillin | Orbenin | Prostaphlin A</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Agoclox | Alclox | Cloxacillin | Cloxaren | Cloxispa | Kamcloxa | Kloxy</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Orbenin</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Cloxacillin fresenius | Cloxin | Orbenin | Rolab-cloxacillin</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Alclox | Cloxacillin | Cloxafil | Cloxasafe | Cloxil | Cloxin | Cloxispa | Klox | Symaclox</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Cloxacillin | Iclox</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-27891788">
<a name="27891788"></a>Ailes EC, Gilboa SM, Gill SK, et al. Association between antibiotic use among pregnant women with urinary tract infections in the first trimester and birth defects, National Birth Defects Prevention Study 1997 to 2011. <i>Birth Defects Res A Clin Mol Teratol</i>. 2016;106(11):940-949. doi:10.1002/bdra.23570<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/27891788/pubmed" id="27891788" target="_blank">27891788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Apotex.1">
<a name="Apotex.1"></a>Apo-Cloxi (cloxacillin) [product monograph]. Weston, Ontario, Canada: Apotex Inc; November 2000.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25614044">
<a name="25614044"></a>Bai AD, Showler A, Burry L, et al. Comparative effectiveness of cefazolin versus cloxacillin as definitive antibiotic therapy for MSSA bacteraemia: results from a large multicentre cohort study. <i>J Antimicrob Chemother</i>. 2015;70(5):1539-1546. doi:10.1093/jac/dku560<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/25614044/pubmed" id="25614044" target="_blank">25614044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26598097">
<a name="26598097"></a>Bookstaver PB, Bland CM, Griffin B, Stover KR, Eiland LS, McLaughlin M. A review of antibiotic use in pregnancy. <i>Pharmacotherapy</i>. 2015;35(11):1052-1062. doi:10.1002/phar.1649<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/26598097/pubmed" id="26598097" target="_blank">26598097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30173161">
<a name="30173161"></a>Burdet C, Loubet P, Le Moing V, et al; CloCeBa study group. Efficacy of cloxacillin versus cefazolin for methicillin-susceptible <i>Staphylococcus aureus</i> bacteraemia (CloCeBa): study protocol for a randomised, controlled, non-inferiority trial. <i>BMJ Open</i>. 2018;8(8):e023151. doi:10.1136/bmjopen-2018-023151<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/30173161/pubmed" id="30173161" target="_blank">30173161</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15138315">
<a name="15138315"></a>Chauhan S, Jain S, Varma S, Chauhan SS. Tropical pyomyositis (myositis tropicans): current perspective. <i>Postgrad Med J</i>. 2004;80(943):267-270. doi:10.1136/pgmj.2003.009274<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/15138315/pubmed" id="15138315" target="_blank">15138315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30121684">
<a name="30121684"></a>Choon SE, Der YS, Lai NLJ, Yu SEE, Yap XL, Nalini NM. Clinical characteristics, culprit drugs and outcome of patients with acute generalised exanthematous pustulosis seen in hospital Sultanah Aminah, Johor Bahru. <i>Med J Malaysia</i>. 2018;73(4):220-225.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/30121684/pubmed" id="30121684" target="_blank">30121684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-SteriMax.1">
<a name="SteriMax.1"></a>Cloxacillin for injection (cloxacillin sodium) [product monograph]. Oakville, Ontario, Canada: SteriMax Inc; February 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19884587">
<a name="19884587"></a>Crider KS, Cleves MA, Reefhuis J, Berry RJ, Hobbs CA, Hu DJ. Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study. <i>Arch Pediatr Adolesc Med</i>. 2009;163(11):978-985. doi:10.1001/archpediatrics.2009.188<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/19884587/pubmed" id="19884587" target="_blank">19884587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34204743">
<a name="34204743"></a>Crochette R, Ravaiau C, Perez L, Coindre JP, Piccoli GB, Blanchi S. Incidence and risk factors for acute kidney injury during the treatment of methicillin-sensitive <i>Staphylococcus aureus</i> infections with cloxacillin based antibiotic regimens: a French retrospective study. <i>J Clin Med</i>. 2021;10(12):2603. doi:10.3390/jcm10122603<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/34204743/pubmed" id="34204743" target="_blank">34204743</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31260651">
<a name="31260651"></a>Damkier P, Brønniche LMS, Korch-Frandsen JFB, Broe A. In utero exposure to antibiotics and risk of congenital malformations: a population-based study. <i>Am J Obstet Gynecol</i>. 2019;221(6):648.e1-648.e15. doi:10.1016/j.ajog.2019.06.050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/31260651/pubmed" id="31260651" target="_blank">31260651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25582344">
<a name="25582344"></a>El Nekidy W, Dziamarski N, Soong D, Donaldson C, Ibrahim M, Kadri A. Cloxacillin-induced seizure in a hemodialysis patient. <i>Hemodial Int</i>. 2015;19(4):E33-E36. doi:10.1111/hdi.12262<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/25582344/pubmed" id="25582344" target="_blank">25582344</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7417768">
<a name="7417768"></a>Enat R, Pollack S, Ben-Arieh Y, et al, “Cholestatic Jaundice Caused by Cloxacillin: Macrophage Inhibition Factor Test in Preventing Rechallenge With Hepatotoxic Drugs,” <i>Br Med J</i>, 1980, 280(6219):982-83.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/7417768/pubmed" id="7417768" target="_blank">7417768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19307354">
<a name="19307354"></a>Euba G, Murillo O, Fernández-Sabé N, et al. Long-term follow-up trial of oral rifampin-cotrimoxazole combination versus intravenous cloxacillin in treatment of chronic staphylococcal osteomyelitis. <i>Antimicrob Agents Chemother</i>. 2009;53(6):2672-2676. doi:10.1128/AAC.01504-08<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/19307354/pubmed" id="19307354" target="_blank">19307354</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Export.DOR">
<a name="Export.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35730139">
<a name="35730139"></a>Faragalla K, Lau H, Wang HL, Liu J. Cloxacillin-induced acute vanishing bile duct syndrome: a case study and literature review. <i>Br J Clin Pharmacol</i>. 2022;88(10):4633-4638. doi:10.1111/bcp.15445<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/35730139/pubmed" id="35730139" target="_blank">35730139</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10493674">
<a name="10493674"></a>García-Porrúa C, González-Gay MA, López-Lázaro L. Drug associated cutaneous vasculitis in adults in northwestern Spain. <i>J Rheumatol</i>. 1999;26(9):1942-1944.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/10493674/pubmed" id="10493674" target="_blank">10493674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9538497">
<a name="9538497"></a>Goland S, Malnick SD, Gratz R, Feldberg E, Geltner D, Sthoeger ZM. Severe cholestatic hepatitis following cloxacillin treatment. <i>Postgrad Med J</i>. 1998;74(867):59-60. doi:10.1136/pgmj.74.867.59<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/9538497/pubmed" id="9538497" target="_blank">9538497</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2915772">
<a name="2915772"></a>Grimm PC, Ogborn MR, Larson AJ, Crocker JF. Interstitial nephritis induced by cloxacillin. <i>Nephron</i>. 1989;51(2):285-286. doi:10.1159/000185306<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/2915772/pubmed" id="2915772" target="_blank">2915772</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26320109">
<a name="26320109"></a>Habib G, Lancellotti P, Antunes MJ, et al; ESC Scientific Document Group. 2015 ESC guidelines for the management of infective endocarditis: the task force for the management of infective endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). <i>Eur Heart J</i>. 2015;36(44):3075-3128. doi:10.1093/eurheartj/ehv319<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/26320109/pubmed" id="26320109" target="_blank">26320109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30593283">
<a name="30593283"></a>Jayaweera JAAS, Abeydeera WPH, Ranasinghe GR. Intravenously administered cloxacillin-induced neutropenia with eosinophilia in a patient with infective endocarditis: a case report. <i>J Med Case Rep</i>. 2018;12(1):384. doi:10.1186/s13256-018-1933-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/30593283/pubmed" id="30593283" target="_blank">30593283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8498418">
<a name="8498418"></a>Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. <i>Am J Obstet Gynecol</i>. 1993;168(5):1393-1399. doi:10.1016/s0002-9378(11)90771-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/8498418/pubmed" id="8498418" target="_blank">8498418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25189188">
<a name="25189188"></a>Lamont HF, Blogg HJ, Lamont RF. Safety of antimicrobial treatment during pregnancy: a current review of resistance, immunomodulation and teratogenicity. <i>Expert Opin Drug Saf</i>. 2014;13(12):1569-1581. doi:10.1517/14740338.2014.939580<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/25189188/pubmed" id="25189188" target="_blank">25189188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29665445">
<a name="29665445"></a>Lavergne A, Vigneau C, Polard E, et al. Acute kidney injury during treatment with high-dose cloxacillin: a report of 23 cases and literature review. <i>Int J Antimicrob Agents</i>. 2018;52(3):344-349. doi:10.1016/j.ijantimicag.2018.04.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/29665445/pubmed" id="29665445" target="_blank">29665445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36401785">
<a name="36401785"></a>Legg A, Meagher N, Johnson SA, et al. Correction to: risk factors for nephrotoxicity in methicillin-resistant Staphylococcus aureus bacteraemia: a post hoc analysis of the CAMERA2 trial. <i>Clin Drug Investig</i>. Published online November 19, 2022. doi:10.1007/s40261-022-01224-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/36401785/pubmed" id="36401785" target="_blank">36401785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35984543">
<a name="35984543"></a>Macheda G, El Helali N, Péan de Ponfilly G, et al. Impact of therapeutic drug monitoring of antibiotics in the management of infective endocarditis. <i>Eur J Clin Microbiol Infect Dis</i>. 2022;41(9):1183-1190. doi:10.1007/s10096-022-04475-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/35984543/pubmed" id="35984543" target="_blank">35984543</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28786715">
<a name="28786715"></a>Mani SSR, Iyyadurai R. Cloxacillin induced agranulocytosis: a rare adverse event of a commonly used antibiotic. <i>Int J Immunopathol Pharmacol</i>. 2017;30(3):297-301. doi:10.1177/0394632017724320<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/28786715/pubmed" id="28786715" target="_blank">28786715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6743732">
<a name="6743732"></a>Matsuda S. Transfer of antibiotics into maternal milk. <i>Biol Res Pregnancy Perinatol</i>. 1984;5(2):57-60.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/6743732/pubmed" id="6743732" target="_blank">6743732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19489710">
<a name="19489710"></a>Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2009;49(1):1-45. doi:10.1086/599376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/19489710/pubmed" id="19489710" target="_blank">19489710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14641124">
<a name="14641124"></a>Moreno-Ancillo A, Domínguez-Noche C, Gil-Adrados AC, Cosmes PM. Near-fatal delayed hypersensitivity reaction to cloxacillin. <i>Contact Dermatitis</i>. 2003;49(1):44-45. doi:10.1111/j.0105-1873.2003.0120d.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/14641124/pubmed" id="14641124" target="_blank">14641124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28461374">
<a name="28461374"></a>Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and risk of spontaneous abortion. <i>CMAJ</i>. 2017b;189(17):E625-E633. doi:10.1503/cmaj.161020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/28461374/pubmed" id="28461374" target="_blank">28461374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28722171">
<a name="28722171"></a>Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and the risk of major congenital malformations: a population based cohort study. <i>Br J Clin Pharmacol</i>. 2017a;83(11):2557-2571. doi:10.1111/bcp.13364<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/28722171/pubmed" id="28722171" target="_blank">28722171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28404586">
<a name="28404586"></a>Nagasayi S, Yan SH, Chiong C. Refractory hypokalaemia in an elderly patient. <i>BMJ</i>. 2017;357:j1575. doi:10.1136/bmj.j1575<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/28404586/pubmed" id="28404586" target="_blank">28404586</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3301235">
<a name="3301235"></a>Nau H. Clinical pharmacokinetics in pregnancy and perinatology. II. Penicillins. <i>Dev Pharmacol Ther</i>. 1987;10(3):174-198. doi:10.1159/000457744<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/3301235/pubmed" id="3301235" target="_blank">3301235</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4595633">
<a name="4595633"></a>Nauta EH, Mattie H, Goslings WR. Pharmacokinetics of cloxacillin in patients on chronic intermittent haemodialysis and in healthy subjects. <i>Chemotherapy</i>. 1973;19(5):261-271. doi:10.1159/000221464<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/4595633/pubmed" id="4595633" target="_blank">4595633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-619055">
<a name="619055"></a>Nelson JD, Howard JB, and Shelton S, “Oral Antibiotic Therapy for Skeletal Infections of Children. I. Antibiotic Concentrations in Suppurative Synovial Fluid,” <i>J Pediatr</i>, 1978, 92(1):131-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/619055/pubmed" id="619055" target="_blank">619055</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17259425">
<a name="17259425"></a>Nunn TR, Cheung WY, and Rollinson PD, “A Prospective Study of Pyogenic Sepsis of the Hip in Childhood,” <i>J Bone Joint Surg Br</i>, 2007, 89(1):100-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/17259425/pubmed" id="17259425" target="_blank">17259425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28332157">
<a name="28332157"></a>Neuville M, El-Helali N, Magalhaes E, et al. Systematic overdosing of oxa- and cloxacillin in severe infections treated in ICU: risk factors and side effects. <i>Ann Intensive Care</i>. 2017;7(1):34. doi:10.1186/s13613-017-0255-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/28332157/pubmed" id="28332157" target="_blank">28332157</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9745311">
<a name="9745311"></a>Pichichero ME, “Group A Beta-Hemolytic Streptococcal Infections,” <i>Pediatr Review</i>, 1998, 19(9):291-302.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/9745311/pubmed" id="9745311" target="_blank">9745311</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19456773">
<a name="19456773"></a>Rodríguez-Jiménez B, Domínguez-Ortega J, Santos-Magadán S, González-García JM, Kindelan-Recarte C. Cloxacillin-induced skin eruption. <i>Clin Exp Dermatol</i>. 2009;34(7):e330-e331. doi:10.1111/j.1365-2230.2009.03281.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/19456773/pubmed" id="19456773" target="_blank">19456773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35740176">
<a name="35740176"></a>Ruch Y, Ursenbach A, Danion F, et al. High incidence of acute kidney injury in patients treated with high-dose amoxicillin and cloxacillin combination therapy. <i>Antibiotics (Basel)</i>. 2022;11(6):770. doi:10.3390/antibiotics11060770<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/35740176/pubmed" id="35740176" target="_blank">35740176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7284928">
<a name="7284928"></a>St. John MA and Prober CG, “Side Effects Of Cloxacillin in Infants and Children,” <i>Can Med Assoc J</i>, 1981, 125(5): 458-60.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/7284928/pubmed" id="7284928" target="_blank">7284928</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Teva.1">
<a name="Teva.1"></a>Teva-Cloxacillin (cloxacillin) [product monograph]. Toronto, Canada: Teva Canada Limited; September 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22005059">
<a name="22005059"></a>Verdier MC, Tribut O, Tattevin P, Michelet C, Bentué-Ferrer D. Assessment of interindividual variability of plasma concentrations after administrazion of high doses of intravenous amoxicillin or cloxacillin in critically ill patients. <i>J Chemother</i>. 2011;23(5):277-281. doi:10.1179/joc.2011.23.5.277<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/22005059/pubmed" id="22005059" target="_blank">22005059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-655134">
<a name="655134"></a>Westerman EL, Bradshaw MW, and Williams TW, “Agranulocytosis During Therapy With Orally Administered Cloxacillin,” <i>Am J Clin Pathol</i>, 1978, 69(5):559-60.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/655134/pubmed" id="655134" target="_blank">655134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/. Accessed May 27, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2001">
<a name="WHO.2001"></a>World Health Organization (WHO). WHO model prescribing information: drugs used in bacterial infections. https://apps.who.int/iris/handle/10665/42372. Published 2001. Accessed June 9, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10090000">
<a name="10090000"></a>Wright AJ, “The Penicillins,” <i>Mayo Clin Proc</i>, 1999, 74(3):290-307.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/10090000/pubmed" id="10090000" target="_blank">10090000</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27446834">
<a name="27446834"></a>Zezos P, Harel Z, Saibil F. Cloxacillin: a new cause of pill-induced esophagitis. <i>Can J Gastroenterol Hepatol</i>. 2016;2016:2904256. doi:10.1155/2016/2904256<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/27446834/pubmed" id="27446834" target="_blank">27446834</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9288 Version 167.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
